Bank of America Corp DE decreased its holdings in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 57.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 759,425 shares of the company's stock after selling 1,033,018 shares during the quarter. Bank of America Corp DE owned 0.50% of Biohaven worth $6,425,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. increased its position in Biohaven by 113.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company's stock worth $36,000 after purchasing an additional 1,268 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Biohaven by 178.4% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company's stock valued at $46,000 after buying an additional 2,583 shares during the last quarter. IFP Advisors Inc grew its stake in shares of Biohaven by 55.4% in the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company's stock valued at $46,000 after buying an additional 1,450 shares in the last quarter. Arax Advisory Partners grew its stake in shares of Biohaven by 943.3% in the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company's stock valued at $55,000 after buying an additional 4,443 shares in the last quarter. Finally, Focus Partners Wealth acquired a new position in Biohaven in the third quarter worth approximately $87,000. Institutional investors and hedge funds own 88.78% of the company's stock.
Key Biohaven News
Here are the key news stories impacting Biohaven this week:
- Positive Sentiment: Major epilepsy licensing agreement: Biohaven licensed its Kv7 ion-channel platform, including lead epilepsy candidate opakalim, to SK Biopharmaceuticals in a deal potentially worth up to $795 million. The agreement includes upfront and milestone payments, plus tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Reuters article
- Positive Sentiment: Validation and potential funding: Opakalim is in Phase 2/3 development for focal epilepsy, and the partnership gives Biohaven a potential source of non-dilutive capital while adding a global development and commercialization partner. The deal also increased investor focus on the company’s broader pipeline. Biohaven and SK Biopharmaceuticals licensing announcement
- Positive Sentiment: Favorable trade-secret ruling: A federal court confirmed that RA Capital and Avilar Therapeutics willfully and maliciously misappropriated a Yale-developed trade secret, formalizing a $4 million award to Biohaven and Yale University. The ruling removes uncertainty around the case and provides a financial recovery for Biohaven. Biohaven trade-secret lawsuit ruling
- Neutral Sentiment: Upcoming clinical catalyst: Investors are awaiting topline results from the RISE3 trial of opakalim, expected in the second half of 2026. The licensing deal improves the commercial outlook, but milestone payments and royalties remain dependent on development, regulatory and sales outcomes. BHVN stock and upcoming trial readout
Biohaven Stock Performance
Biohaven stock opened at $17.12 on Thursday. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57. The stock has a 50-day simple moving average of $14.74 and a 200 day simple moving average of $11.83. The stock has a market capitalization of $2.59 billion, a price-to-earnings ratio of -3.69 and a beta of 1.26. The company has a quick ratio of 4.73, a current ratio of 4.73 and a debt-to-equity ratio of 21.23.
Biohaven (NYSE:BHVN - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, research analysts anticipate that Biohaven Ltd. will post -3.29 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on BHVN. Needham & Company LLC set a $11.00 price objective on shares of Biohaven in a research report on Monday, June 29th. Bank of America reaffirmed an "underperform" rating and set a $11.00 target price (down from $12.00) on shares of Biohaven in a research report on Monday, June 29th. TD Cowen reaffirmed a "buy" rating on shares of Biohaven in a research report on Wednesday. Morgan Stanley raised their price objective on shares of Biohaven from $18.00 to $19.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen upgraded Biohaven from a "strong sell" rating to a "sell" rating in a research note on Saturday, June 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $18.94.
Get Our Latest Stock Report on BHVN
About Biohaven
(
Free Report)
Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.
The company's most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
